阿片类药物使用障碍全球市场规模、份额、趋势和成长分析报告（2026-2034）

阿片类药物使用障碍市场预计将从 2025 年的 60.7 亿美元成长到 2034 年的 170.6 亿美元，2026 年至 2034 年的复合年增长率为 12.17%。

随着医疗保健系统将重点放在有效的治疗策略和危害缓解措施上，阿片类药物使用障碍市场正在经历重大变革时期。阿片类药物成瘾和过量用药案例的增加，推动了对先进治疗性介入，包括Buprenornhine、美沙酮和新兴的非鸦片类药物疗法。结合药物治疗支持（MAT）、行为疗法和数位化药物依从性监测的综合护理模式，对于长期康復至关重要。监管措施和公共卫生宣传活动正在进一步加速患者获得创新治疗方法。

技术和临床的进步正在提升治疗的有效性和可近性。数位健康平台提供远端监测、风险预测预警和用药依从性追踪等功能，从而实现个人化治疗策略。新型药物製剂，例如缓释製剂和舌下给药系统，在提高患者依从性的同时，也降低了药物滥用的风险。对非依赖性镇痛药、疫苗干预和神经调控疗法的研究正在开闢新的治疗途径。医疗服务提供者正积极利用远端医疗和行动医疗技术，扩大服务不足人口的就医范围，并提高介入措施的成功率。

未来的发展将由综合公共卫生策略、政策支援和药物创新共同塑造。北美地区由于其高发病率和成熟的治疗体系，仍然是最大的市场；同时，新兴经济体获得实证治疗的机会也逐渐扩大。医疗服务提供者、数位健康创新者和製药公司之间的策略合作正在建立一个全面支持诊断、治疗和復健的生态系统。随着公众意识的提高、技术的进步和治疗方案的增多，阿片类药物使用障碍市场有望提供更有效、以患者为中心的解决方案，以应对医疗和社会方面的挑战。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球阿片类药物使用障碍市场：依药物分类

• 市场分析、洞察与预测
• 纳曲酮
• Buprenornhine
• 梅萨顿
• 其他的

第五章 全球鸦片类药物使用障碍市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 注射给药
• 其他的

第六章：全球鸦片类药物使用障碍市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 其他的

第七章 全球鸦片类药物使用障碍市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Indivior PLC
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Collegium Pharmaceutical（BioDelivery Sciences International Inc.）
  • Alkermes Inc
  • Orexo US Inc.（A Part Of Orexo AB）
  • Titan Pharmaceuticals Inc
  • Omeros Corporation
  • Camurus AB
  • Hikma Pharmaceuticals PLC

The Opioids Use Disorder Market size is expected to reach USD 17.06 Billion in 2034 from USD 6.07 Billion (2025) growing at a CAGR of 12.17% during 2026-2034.

The opioids use disorder market is undergoing significant evolution as healthcare systems prioritize effective treatment strategies and harm reduction measures. Rising prevalence of opioid dependence and overdose incidents has intensified demand for advanced therapeutic interventions, including buprenorphine, methadone, and emerging non-opioid pharmacotherapies. Integrated care models combining medication-assisted treatment (MAT), behavioral therapy, and digital adherence monitoring are becoming essential for long-term recovery outcomes. Regulatory initiatives and public health campaigns are further supporting patient access to innovative therapies.

Technological and clinical advancements are expanding treatment efficacy and accessibility. Digital health platforms provide remote monitoring, predictive risk alerts, and adherence tracking, enabling personalized treatment strategies. Novel drug formulations, including extended-release and sublingual delivery systems, are improving patient compliance while reducing misuse potential. Research into non-addictive analgesics, vaccine-based interventions, and neuromodulation therapies is creating new therapeutic avenues. Healthcare providers are increasingly leveraging telemedicine and mobile health technologies to reach underserved populations and improve intervention success rates.

The future trajectory is defined by integrated public health strategies, policy support, and pharmaceutical innovation. North America remains the largest market due to high prevalence and mature treatment infrastructure, while emerging economies are gradually scaling access to evidence-based therapies. Strategic partnerships between healthcare providers, digital health innovators, and pharmaceutical companies are fostering a comprehensive ecosystem for diagnosis, treatment, and recovery support. As awareness, technology, and therapeutic options expand, the opioids use disorder market is poised to provide more effective, patient-centric solutions that address both medical and societal challenges.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug

• Naltrexone
• Buprenorphine
• Methadone
• Others

By Route of Administration

• Oral Administration
• Injectable Administration
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Indivior PLC, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Collegium Pharmaceutical BioDelivery Sciences International Inc, Alkermes Inc, Orexo US Inc a part of Orexo AB, Titan Pharmaceuticals Inc, Omeros Corporation, Camurus AB, Hikma Pharmaceuticals PLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OPIOIDS USE DISORDER MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Naltrexone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Buprenorphine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Methadone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OPIOIDS USE DISORDER MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OPIOIDS USE DISORDER MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OPIOIDS USE DISORDER MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OPIOIDS USE DISORDER INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Indivior PLC
  • 9.2.2 Teva Pharmaceutical Industries Ltd
  • 9.2.3 Pfizer Inc
  • 9.2.4 Collegium Pharmaceutical (BioDelivery Sciences International Inc.)
  • 9.2.5 Alkermes Inc
  • 9.2.6 Orexo US Inc. (A Part Of Orexo AB)
  • 9.2.7 Titan Pharmaceuticals Inc
  • 9.2.8 Omeros Corporation
  • 9.2.9 Camurus AB
  • 9.2.10 Hikma Pharmaceuticals PLC